(Q30984470)

28 June 2017

1 reference

title

Emerging drugs for moderate-to-severe psoriasis (English)

1 reference

28 June 2017

Melissa A Magliocco

1

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Emerging Drugs

28 June 2017

published in

1 reference

28 June 2017

volume

10

1 reference

28 June 2017

issue

1

1 reference

28 June 2017

page(s)

35-52

1 reference

The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Skin‐infiltrating Lymphocytes in Normal and Disordered Skin: Activation Signals and Functional Roles in Psoriasis and Mycosis Fungoides‐type Cutaneous T Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Targeting tumor necrosis factor-alpha in the therapy of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Pharmacology of adapalene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Methotrexate induces differentiation of human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Novel therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Immune deviation strategies in the therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Alefacept therapy produces remission for patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Current treatment of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

The immunologic basis for the treatment of psoriasis with new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Recombinantly engineered human proteins: transforming the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Mycophenolate in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Pimecrolimus for the treatment of inflammatory skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Tacrolimus ointment improves psoriasis in a microplaque assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

A phase II multicenter clinical trial of systemic bexarotene in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Advances in psoriasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

Fine Mapping of the PSORS4 Psoriasis Susceptibility Region on Chromosome 1q21

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.35

21 January 2018

Identifiers

DOI

10.1517/14728214.10.1.35

1 reference

28 June 2017

1 reference